Regulus Therapeutics Announces Poster Presentation at ASN Kidney Week 2022
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced a poster presentation at ASN Kidney Week 2022 in Orlando, showcasing data on RGLS8429, a next-generation oligonucleotide targeting microRNAs for treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). The session will be led by Dr. Edmund Lee on November 3, 2022, highlighting the potential of RGLS8429 to improve kidney function and reduce disease severity based on preclinical studies. ADPKD affects around 160,000 individuals in the U.S. and has a global prevalence of 4 to 7 million.
- RGLS8429 demonstrates significant improvements in kidney function and disease severity in preclinical models.
- Presentation at a major medical conference (ASN Kidney Week 2022) enhances visibility and credibility of RGLS8429.
- None.
SAN DIEGO, Oct. 27, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced a poster presentation at the American Society of Nephrology Kidney Week 2022 (ASN Kidney Week 2022), which will take place in Orlando, November 3-6, 2022.
The poster, titled "Discovery of Next-generation Anti-miR-17 Oligonucleotide RGLS8429 for Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)," provides an overview of the data supporting the potential of RGLS8429 as a treatment for ADPKD.
Details of the poster presentation are as follows:
Session Title: Genetic Diseases of the Kidneys: Cystic - I
Presenter: Edmund Lee, Ph.D., Executive Director of Biology at Regulus
Location: Exhibit Hall, Orange County Convention Center, West Building
Date and Time: November 3, 2022 from 10:00 a.m. to 12:00 p.m.
Abstract Number: 3768400
About ADPKD
Autosomal Dominant Polycystic Kidney Disease (ADPKD), caused by mutations in the PKD1 or PKD2 genes, is among the most common human monogenic disorders and a leading cause of end-stage renal disease. The disease is characterized by the development of multiple fluid filled cysts primarily in the kidneys, and to a lesser extent in the liver and other organs. Excessive kidney cyst cell proliferation, a central pathological feature, ultimately leads to end-stage renal disease in approximately
About RGLS8429
RGLS8429 is a novel, next generation oligonucleotide for the treatment of ADPKD designed to inhibit miR-17 and to preferentially target the kidney. Administration of RGLS8429 has shown robust data in preclinical models, where clear improvements in kidney function, size, and other measures of disease severity have been demonstrated along with a superior pharmacologic profile in preclinical studies compared to Regulus' first-generation compound.
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in San Diego, CA.
Forward-Looking Statements
Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the Company's RGLS8429 program, including the expected timing for initiating clinical studies, the expected timing for reporting topline data, and the timing and future occurrence of other preclinical and clinical activities. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and in the endeavor of building a business around such drugs, and the risk additional toxicology data may be negative. In addition, while Regulus expects the COVID-19 pandemic to adversely affect its business operations and financial results, the extent of the impact on Regulus' ability to achieve its preclinical and clinical development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease. These and other risks are described in additional detail in Regulus' filings with the Securities and Exchange Commission, including under the "Risk Factors" heading of Regulus most recently quarterly report on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
View original content to download multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-poster-presentation-at-asn-kidney-week-2022-301661514.html
SOURCE Regulus Therapeutics Inc.
FAQ
What is the focus of Regulus Therapeutics?
What is RGLS8429?
When is the poster presentation for RGLS8429?
What does the data for RGLS8429 suggest?
How prevalent is Autosomal Dominant Polycystic Kidney Disease?
